SCHEMBL6403951

SCHEMBL6403951

Cc1[nH]c2ccccc2c1C=C1C(=O)Nc2ccc(C(=O)O)cc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLK2 Q86UE8 6/20 0.55
▸ PDPK1 O15530 1/20 0.55
▸ JAK3 P52333 1/20 0.55
▸ KDR P35968 4/20 0.53
▸ PDGFRB P09619 3/20 0.53
▸ FGFR1 P11362 3/20 0.53
▸ CDK1 P06493 4/20 0.51
▸ CCNB1 P14635 4/20 0.51
▸ CDK2 P24941 3/20 0.51
▸ CCNA2 P20248 1/20 0.51
▸ CCNE1 P24864 1/20 0.51
▸ CDK7 P50613 1/20 0.51
▸ CCNH P51946 1/20 0.51
▸ MNAT1 P51948 1/20 0.51
▸ CDK5 Q00535 1/20 0.51
▸ CDK5R1 Q15078 1/20 0.51
▸ AURKB Q96GD4 1/20 0.51
▸ CCNB2 O95067 1/20 0.49
▸ CCNB3 Q8WWL7 1/20 0.49
▸ SRC P12931 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411135 1.00 TLK2 (0.55) TLK2PDPK1JAK3KDRPDGFRB
SCHEMBL5203968 0.85 PDPK1 (0.57) PDPK1KDRPDGFRBCDK1CCNB1
SCHEMBL6395356 0.85 KDR (0.61) TLK2PDPK1JAK3KDRPDGFRB
SCHEMBL6395359 0.85 KDR (0.61) TLK2PDPK1JAK3KDRPDGFRB
SCHEMBL7136537 0.83 CDK1 (0.54) KDRPDGFRBFGFR1CDK1CCNB1
SCHEMBL6405756 0.83 ALK (0.56) PDPK1CDK1CCNB1CDK2CCNA2
SCHEMBL6405753 0.83 ALK (0.56) PDPK1CDK1CCNB1CDK2CCNA2
SCHEMBL5841215 0.83 SYK (0.52) PDPK1KDRPDGFRBFGFR1CDK1
SCHEMBL5841219 0.83 SYK (0.52) PDPK1KDRPDGFRBFGFR1CDK1
SCHEMBL5203890 0.82 AURKB (0.72) PDPK1JAK3KDRPDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 — — US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 — — US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 — — US disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 TLK2 413/4885PDPK1 45/4885JAK3 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback